Axovant Gene Therapies (NASDAQ:AXGT) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.
This is a breakdown of current ratings and recommmendations for Axovant Gene Therapies and Synlogic, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axovant Gene Therapies||0||1||8||0||2.89|
Axovant Gene Therapies currently has a consensus target price of $27.40, indicating a potential upside of 455.75%. Synlogic has a consensus target price of $15.29, indicating a potential upside of 558.87%. Given Synlogic’s higher probable upside, analysts clearly believe Synlogic is more favorable than Axovant Gene Therapies.
Earnings & Valuation
This table compares Axovant Gene Therapies and Synlogic’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Axovant Gene Therapies||N/A||N/A||-$129.07 million||($8.02)||-0.61|
|Synlogic||$2.52 million||29.20||-$48.44 million||($2.03)||-1.14|
Synlogic has higher revenue and earnings than Axovant Gene Therapies. Synlogic is trading at a lower price-to-earnings ratio than Axovant Gene Therapies, indicating that it is currently the more affordable of the two stocks.
This table compares Axovant Gene Therapies and Synlogic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axovant Gene Therapies||N/A||-236.19%||-79.86%|
Risk & Volatility
Axovant Gene Therapies has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.
Institutional and Insider Ownership
13.8% of Axovant Gene Therapies shares are held by institutional investors. Comparatively, 65.0% of Synlogic shares are held by institutional investors. 6.6% of Axovant Gene Therapies shares are held by company insiders. Comparatively, 21.9% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Synlogic beats Axovant Gene Therapies on 9 of the 12 factors compared between the two stocks.
About Axovant Gene Therapies
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.